Shentao Ruangan Granule

Shentao Ruangan Granule is a Traditional Chinese Medicine (TCM) formulation developed by The First Affiliated Hospital of Guangzhou University of Chinese Medicine. It is primarily investigated as an adjunctive therapy for patients with primary liver cancer (hepatocellular carcinoma) who are receiving conventional anti-tumor treatments. The formulation is designed according to TCM principles to "soften the liver" (Ruangan), a term typically associated with addressing liver fibrosis and cirrhosis, and to improve symptom clusters and TCM syndrome patterns in cancer patients. Clinical research, such as the prospective observational study ChiCTR2300074519, focuses on identifying patient populations most sensitive to the granule and evaluating its impact on liver cancer-specific quality of life and tongue and pulse features.

Other names

参桃软肝颗粒Shen Tao Ruan Gan Granule